Gilead Sciences (GILD) Prices $2B Notes Offering

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1 billion of 5.250% senior notes maturing in 2033 and $1 billion of 5.550% senior notes maturing in 2053. The offering is expected to close September 14, 2023, subject to customary closing conditions.

You May Also Be Interested In

• Gilead donates remdesivir to Uganda for Ebola outbreak response
• Gilead and Merck announce successful HIV treatment trial results
• Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief